Skip to main content

Beneficial ownership — 13D / 13G

87,314 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
AWM Investment Company, Inc. BRCNF Burcon NutraScience Corp 13G 6.7% 2y
Thomas A. Satterfield, Jr. ALCO Alico, Inc. 13G/A 7.52% 2y
ARMISTICE CAPITAL, LLC XRTX XORTX Therapeutics Inc. 13G/A 4.99% 2y
FRONTIER CAPITAL MANAGEMENT CO.,LLC TILE Interface Inc 13G/A 5.23% 2y
Ronald M. Shaich CAVA Cava Group, Inc. 13G 10.3% 2y
Nan Shan Life Insurance Co., Ltd. TRTX TPG RE Finance Trust, Inc. 13G/A 3.67% 2y
Deer IX & Co. L.P. TOST Toast, Inc. 13G/A 4% 2y
Park West Asset Management LLC UTI Universal Technical Institute Inc 13G/A 5.3% 2y
PRICE T ROWE ASSOCIATES INC /MD/ HIG Hartford Insurance Group, Inc. 13G/A 6.2% 2y
ARMISTICE CAPITAL, LLC BFRI Biofrontera Inc. 13G 9.99% 2y
Deep Track Capital, LP ESPR Esperion Therapeutics, Inc. 13G/A 0% 2y
FIR TREE CAPITAL MANAGEMENT LP PFTA Perception Capital Corp. III Class A Ordinary Share 13G 5.08% 2y
Deep Track Capital, LP IMVT Immunovant, Inc. 13G/A 0.69% 2y
Newtyn Management, LLC TECX Tectonic Therapeutic, Inc. 13G 6.1% 2y
Driehaus Capital Management LLC XENE Xenon Pharmaceuticals Inc. 13G/A 5.88% 2y
Lytton, Laurence W. BIOL Biolase, Inc. 13G/A 0.6% 2y
Aristotle Capital Management, LLC RPM Rpm International Inc 13G/A 7.43% 2y
Fund 1 Investments, LLC JILL J.Jill, Inc. 13G/A 3.36% 2y
PRICE T ROWE ASSOCIATES INC /MD/ ENTG Entegris Inc 13G 8.1% 2y
MARSHFIELD ASSOCIATES STRA Strategic Education, Inc. 13G/A 7.61% 2y
BIOTECHNOLOGY VALUE FUND L P ELDN Eledon Pharmaceuticals, Inc. 13G/A 17.9% 2y
EcoR1 Capital, LLC KURA Kura Oncology, Inc. 13G/A 9.99% 2y
ARMISTICE CAPITAL, LLC SCNI Scinai Immunotherapeutics Ltd. 13G 9.99% 2y
Third Rock Ventures IV, L.P. FULC Fulcrum Therapeutics, Inc. 13G/A 3.8% 2y
Cormorant Asset Management, LP ATXS Astria Therapeutics, Inc. Common Stock 13G/A 0% 2y
683 Capital Management, LLC CDLX Cardlytics, Inc. 13G/A 4.6% 2y
T. Rowe Price Investment Management, Inc. FSBC Five Star Bancorp 13G 8% 2y
ARMISTICE CAPITAL, LLC PALI Palisade Bio, Inc. 13G/A 4.99% 2y
ALLIANCEBERNSTEIN L.P. ATRC AtriCure, Inc. 13G/A 7.2% 2y
BIOTECHNOLOGY VALUE FUND L P CNTA Centessa Pharmaceuticals plc 13G/A 9% 2y
Shay Capital LLC XELA Exela Technologies, Inc. Common Stock 13G/A 8.23% 2y
Westchester Capital Management, LLC ALSAF Alpha Star Acquisition Corp 13G 7.17% 2y
FRONTIER CAPITAL MANAGEMENT CO.,LLC MOD Modexus Solutions, Inc. 13G/A 2.86% 2y
Tarsadia Capital, LLC SHO Sunstone Hotel Investors, Inc. 13G/A 2.2% 2y
Fundsmith LLP MKC Mccormick & Co Inc 13G/A 7.6% 2y
NOMURA HOLDINGS INC AYRWF Ayr Wellness Inc. 13G/A 0% 2y
Hugh S. Griffith NCNA NuCana plc 13G/A 11% 2y
RTW INVESTMENTS, LP SABS SAB Biotherapeutics, Inc. 13G 9.99% 2y
CONTINENTAL GENERAL INSURANCE CO SDIG Stronghold Digital Mining, Inc. Class A Common Stock 13G/A 9.99% 2y
Hillhouse Investment Management, Ltd. LEGN Legend Biotech Corp 13G/A 3.6% 2y
RTW INVESTMENTS, LP IMUX Immunic, Inc. 13G/A 9.6% 2y
GLAZER CAPITAL, LLC MVLA Movella Holdings Inc. Common Stock 13G/A 0% 2y
Nuveen Asset Management, LLC ALT Altimmune, Inc. 13G/A 2.88% 2y
ALLIANCEBERNSTEIN L.P. RMBI Richmond Mutual Bancorporation, Inc. 13G/A 7.2% 2y
BAKER BROS. ADVISORS LP ADAPY Adaptimmune Therapeutics PLC 13G/A 4.8% 2y
T. Rowe Price Investment Management, Inc. ALHC Alignment Healthcare, Inc. 13G 6.4% 2y
Olivier Pomel DDOG Datadog, Inc. 13G/A 6.1% 2y
ARMISTICE CAPITAL, LLC QTEX QTREX Quantum Ltd. 13G 9.89% 2y
T. Rowe Price Investment Management, Inc. ACHC Acadia Healthcare Company, Inc. 13G/A 9.3% 2y
Greenhouse Funds LLLP CDRE Cadre Holdings, Inc. 13G 6.6% 2y